Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-pac...
Saved in:
Published in | Nature medicine Vol. 30; no. 1; pp. 249 - 256 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
2024
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (
n
= 353; experimental arm) versus placebo and nab-P (
n
= 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470–0.906,
P
= 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414–0.914,
P
= 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier
NCT03777579
.
In this prespecified analysis of the ongoing TORCHLIGHT phase 3 trial, first-line treatment with toripalimab and nab-paclitaxel in patients with advanced triple-negative breast cancer led to significantly longer progression-free survival in the PD-L1-positive population compared to nab-paclitaxel alone. |
---|---|
AbstractList | The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470-0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414-0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 .The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470-0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414-0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 . The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) ( n = 353; experimental arm) versus placebo and nab-P ( n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470–0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414–0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 . In this prespecified analysis of the ongoing TORCHLIGHT phase 3 trial, first-line treatment with toripalimab and nab-paclitaxel in patients with advanced triple-negative breast cancer led to significantly longer progression-free survival in the PD-L1-positive population compared to nab-paclitaxel alone. The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470–0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414–0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579.In this prespecified analysis of the ongoing TORCHLIGHT phase 3 trial, first-line treatment with toripalimab and nab-paclitaxel in patients with advanced triple-negative breast cancer led to significantly longer progression-free survival in the PD-L1-positive population compared to nab-paclitaxel alone. The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470-0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414-0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 . |
Author | Deng, Rong Wang, Xiaojia Liu, Xinlan Wu, Yudong Li, Fanfan Sheng, Yuan Yu, Wenbo Sun, Tao Wang, Jingfen Wu, Xinhong Chen, Yiding Cui, Jiuwei Yan, Min Zhang, Anqin Zhang, Lili Lin, Ying Ouyang, Quchang Wang, Haibo Cang, Shundong Mo, Xueli Teng, Yuee Geng, Cuizhi Luo, Xianming Pan, Yueyin Yin, Yongmei Zhou, Xin Liu, Qiang Yi, Tienan Wang, Kun Keegan, Patricia Jiang, Zefei Yang, Chaoqiang Gu, Kangsheng Cheng, Ying Wang, Hongxia Qian, Jun Cheng, Jing Wu, Xiaohong Li, Man Xie, Chunwei Yang, Junlan Zhang, Yongqiang Chen, Lilin Zhang, Helong Sun, Gang Zhang, Qingyuan Wang, Chuan Han, Yunwei Xiong, Huihua Wang, Yongsheng Fu, Peifen Li, Hui Pang, Danmei Yang, Jin Zang, Aimin Nie, Jianyun Wang, Shusen Li, Qingshan |
Author_xml | – sequence: 1 givenname: Zefei orcidid: 0000-0002-4295-0173 surname: Jiang fullname: Jiang, Zefei email: jiangzefei@csco.org.cn organization: Fifth Medical Center of Chinese PLA General Hospital – sequence: 2 givenname: Quchang surname: Ouyang fullname: Ouyang, Quchang organization: Breast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University – sequence: 3 givenname: Tao orcidid: 0000-0001-5931-386X surname: Sun fullname: Sun, Tao organization: Breast Medicine Ward Area I, Liaoning Cancer Hospital – sequence: 4 givenname: Qingyuan surname: Zhang fullname: Zhang, Qingyuan organization: Department of Breast & Lymphoma, Harbin Medical University Cancer Hospital – sequence: 5 givenname: Yuee surname: Teng fullname: Teng, Yuee organization: Department of Medical Oncology, The First Hospital of China Medical University – sequence: 6 givenname: Jiuwei surname: Cui fullname: Cui, Jiuwei organization: Oncology Center, Oncology Department, The First Hospital of Jilin University – sequence: 7 givenname: Haibo orcidid: 0000-0002-7514-1719 surname: Wang fullname: Wang, Haibo organization: Breast Disease Center, The Affiliated Hospital of Qingdao University – sequence: 8 givenname: Yongmei orcidid: 0000-0003-3335-369X surname: Yin fullname: Yin, Yongmei organization: Department of Oncology, Jiangsu Province Hospital – sequence: 9 givenname: Xiaojia orcidid: 0000-0002-7005-0842 surname: Wang fullname: Wang, Xiaojia organization: Department of Breast (Mammary Gland) Disease, Zhejiang Cancer Hospital – sequence: 10 givenname: Xin surname: Zhou fullname: Zhou, Xin organization: The Breast Cancer Center, Chongqing University Cancer Hospital – sequence: 11 givenname: Yongsheng surname: Wang fullname: Wang, Yongsheng organization: Breast Surgery, Shandong Cancer Hospital – sequence: 12 givenname: Gang surname: Sun fullname: Sun, Gang organization: Breast Medicine Department, Xinjiang Medical University Affiliated Cancer Hospital – sequence: 13 givenname: Jingfen surname: Wang fullname: Wang, Jingfen organization: Breast Medicine Department, Linyi Cancer Hospital – sequence: 14 givenname: Lili surname: Zhang fullname: Zhang, Lili organization: Department of Oncology, Jiangsu Cancer Hospital – sequence: 15 givenname: Jin surname: Yang fullname: Yang, Jin organization: Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University – sequence: 16 givenname: Jun surname: Qian fullname: Qian, Jun organization: Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College – sequence: 17 givenname: Min orcidid: 0000-0002-3911-748X surname: Yan fullname: Yan, Min organization: Breast Surgery, Henan Cancer Hospital – sequence: 18 givenname: Xinlan surname: Liu fullname: Liu, Xinlan organization: Department of Medical Oncology, General Hospital of Ningxia Medical University – sequence: 19 givenname: Tienan surname: Yi fullname: Yi, Tienan organization: Department of Oncology, Xiangyang Central Hospital – sequence: 20 givenname: Ying orcidid: 0000-0001-9908-597X surname: Cheng fullname: Cheng, Ying organization: Department of Medical Oncology, Jilin Cancer Hospital – sequence: 21 givenname: Man surname: Li fullname: Li, Man organization: Department of Medical Oncology, The Second Hospital of Dalian Medical University – sequence: 22 givenname: Aimin surname: Zang fullname: Zang, Aimin organization: Department of Medical Oncology, Affiliated Hospital of Hebei University – sequence: 23 givenname: Shusen orcidid: 0000-0003-0139-5780 surname: Wang fullname: Wang, Shusen organization: Internal Medicine Department, Sun Yat-sen University Cancer Center – sequence: 24 givenname: Chuan surname: Wang fullname: Wang, Chuan organization: Breast Surgery, Fujian Medical University Union Hospital – sequence: 25 givenname: Xinhong surname: Wu fullname: Wu, Xinhong organization: Galactophore Department, Hubei Cancer Hospital – sequence: 26 givenname: Jing surname: Cheng fullname: Cheng, Jing organization: Galactophore Department, Union Hospital Tongji Medical College of Hust – sequence: 27 givenname: Hui surname: Li fullname: Li, Hui organization: Breast Surgery, Sichuan Cancer Hospital – sequence: 28 givenname: Ying orcidid: 0000-0002-5923-3306 surname: Lin fullname: Lin, Ying organization: Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University – sequence: 29 givenname: Cuizhi surname: Geng fullname: Geng, Cuizhi organization: Department of Breast Cancer, The Fourth Hospital of Hebei Medical University – sequence: 30 givenname: Kangsheng surname: Gu fullname: Gu, Kangsheng organization: Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University – sequence: 31 givenname: Chunwei surname: Xie fullname: Xie, Chunwei organization: Breast Surgery, Nanchang People’s Hospital – sequence: 32 givenname: Huihua surname: Xiong fullname: Xiong, Huihua organization: Department of Oncology, Tongji Hospital Tongji Medical College of Hust – sequence: 33 givenname: Xiaohong surname: Wu fullname: Wu, Xiaohong organization: Department of Oncology, Affiliated Hospital of Jiangnan University – sequence: 34 givenname: Junlan surname: Yang fullname: Yang, Junlan organization: Department of Medical Oncology, The First Medical Center of the General Hospital of the People’s Liberation Army of China – sequence: 35 givenname: Qingshan surname: Li fullname: Li, Qingshan organization: Department of Oncology, Affiliated Hospital of Chengde Medical University – sequence: 36 givenname: Yiding orcidid: 0000-0002-2263-6275 surname: Chen fullname: Chen, Yiding organization: Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine – sequence: 37 givenname: Fanfan orcidid: 0000-0003-4116-1604 surname: Li fullname: Li, Fanfan organization: Department of Oncology, The Second Affiliated Hospital of Anhui University – sequence: 38 givenname: Anqin surname: Zhang fullname: Zhang, Anqin organization: Breast Surgery Department, Guandong Maternal Hospital, Guandong Children’s Hospital – sequence: 39 givenname: Yongqiang surname: Zhang fullname: Zhang, Yongqiang organization: Department of Medical Oncology, Beijing Hospital – sequence: 40 givenname: Yudong surname: Wu fullname: Wu, Yudong organization: Breast Surgery, Jiangxi Cancer Hospital – sequence: 41 givenname: Jianyun orcidid: 0000-0003-3691-8940 surname: Nie fullname: Nie, Jianyun organization: Third department of Breast surgery, Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University) – sequence: 42 givenname: Qiang surname: Liu fullname: Liu, Qiang organization: Breast Surgery Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University – sequence: 43 givenname: Kun surname: Wang fullname: Wang, Kun organization: Department of Breast Oncology, Guangdong Provincial People’s Hospital – sequence: 44 givenname: Xueli surname: Mo fullname: Mo, Xueli organization: Breast Disease Department, Peking University Shougang Hospital – sequence: 45 givenname: Lilin surname: Chen fullname: Chen, Lilin organization: Department of Medical Oncology, The First Affiliated Hospital of Xiamen University – sequence: 46 givenname: Yueyin orcidid: 0000-0003-0532-5368 surname: Pan fullname: Pan, Yueyin organization: Oncology Chemotherapy Department, First Affiliated Hospital of USTC (Anhui Provincial Hospital) – sequence: 47 givenname: Peifen surname: Fu fullname: Fu, Peifen organization: Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 48 givenname: Helong surname: Zhang fullname: Zhang, Helong organization: Department of Medical Oncology, The Second Affiliated Hospital of the Air Force Medical University of the People’s Liberation Army Chinese People’s Liberation Army – sequence: 49 givenname: Danmei surname: Pang fullname: Pang, Danmei organization: Breast Oncology Department, The First People’s Hospital of Foshan – sequence: 50 givenname: Yuan surname: Sheng fullname: Sheng, Yuan organization: Thyroid and Breast Surgery Department, Changhai Hospital of Shanghai – sequence: 51 givenname: Yunwei surname: Han fullname: Han, Yunwei organization: Department of Oncology, The Affiliated Hospital of Southwest Medical University – sequence: 52 givenname: Hongxia surname: Wang fullname: Wang, Hongxia organization: Department of Oncology, Shanghai General Hospital, Fudan University Shanghai Cancer Center – sequence: 53 givenname: Shundong surname: Cang fullname: Cang, Shundong organization: Department of Medical Oncology, Henan Provincial People’s Hospital – sequence: 54 givenname: Xianming surname: Luo fullname: Luo, Xianming organization: Shanghai Junshi Biosciences – sequence: 55 givenname: Wenbo surname: Yu fullname: Yu, Wenbo organization: Shanghai Junshi Biosciences – sequence: 56 givenname: Rong surname: Deng fullname: Deng, Rong organization: Shanghai Junshi Biosciences – sequence: 57 givenname: Chaoqiang surname: Yang fullname: Yang, Chaoqiang organization: Shanghai Junshi Biosciences – sequence: 58 givenname: Patricia orcidid: 0000-0002-7266-395X surname: Keegan fullname: Keegan, Patricia organization: TopAlliance Biosciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38191615$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtrFTEYhoO02Iv-ARcScOMmNpfJzZ0Ub1Do5iy6C5nMN3VKJjMmGTn6683xVAUXLkIC3_O-CXku0ElaEiD0gtE3jApzVTomLSOUi7aU1mT_BJ0z2SnCNL07aWeqDTFWqjN0UcoDpVRQaZ-iM2GYZYrJc1R3S55WH6fZ93iNW8HJ92T1IU7V7yHiKeEZqi_V1yngJeMMYcsZUsW1JSOQBPdt9g1wn6FxOPgUIL_FHmefhmWefsCA1y--ABaHjI_P0OnoY4Hnj_sl2n14v7v-RG5uP36-fndDgtCykoGagRmhqfLUGyvsYATvQVHd-1EE0Rs2hpEaHXxHmemE5LxTiuvR2I5ZcYleH2vXvHzdoFQ3TyVAjD7BshXHLeOSS8FZQ1_9gz4sW07tcQdKd5wZpRvFj1TISykZRrfm9nH5u2PUHZS4oxLXlLhfSty-hV4-Vm_9DMOfyG8HDRBHoLRRuof89-7_1P4EkUqZOA |
CitedBy_id | crossref_primary_10_3390_cancers16122189 crossref_primary_10_1016_j_annonc_2024_04_001 crossref_primary_10_1038_s41591_024_03088_2 crossref_primary_10_1016_j_eclinm_2024_102700 |
Cites_doi | 10.3322/caac.21660 10.1200/JCO.20.02712 10.1038/s41572-020-0160-6 10.1056/NEJMoa2202809 10.1200/JCO.2020.38.15_suppl.5040 10.1001/jama.2018.19323 10.1158/1535-7163.MCT-17-0386 10.1200/JCO.22.00727 10.18632/oncotarget.27877 10.1038/s41591-021-01444-0 10.1200/JCO.2019.37.15_suppl.e20690 10.21037/atm.2019.09.08 10.1158/1078-0432.CCR-19-3922 10.1056/NEJMoa1809615 10.1016/j.annonc.2021.05.801 10.1002/cac2.12068 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer Nature America, Inc. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature America, Inc. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
DBID | NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
DOI | 10.1038/s41591-023-02677-x |
DatabaseName | PubMed CrossRef Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Toxicology Abstracts Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Genetics Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1546-170X |
EndPage | 256 |
ExternalDocumentID | 10_1038_s41591_023_02677_x 38191615 |
Genre | Journal Article |
GrantInformation_xml | – fundername: This study was sponsored by Shanghai Junshi Biosciences. This work was supported by National Major Science & Technology Major Projects (2017ZX09302009) and Shanghai Science and Technology Committee Technology Grant (17431900700). |
GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 3V. 4.4 53G 5BI 5M7 5RE 5S5 70F 7X7 85S 88A 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAEEF AARCD AAYOK AAZLF ABAWZ ABCQX ABDBF ABEFU ABJNI ABLJU ABOCM ABUWG ABVXF ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ADBBV ADFRT AENEX AFBBN AFKRA AFRAH AFSHS AGAYW AGCDD AGEZK AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CS3 DB5 DU5 DWQXO EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA G8K GNUQQ GUQSH GX1 HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M0L M1P M2O M2P M7P MK0 N9A NADUK NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M AAYZH NPM AAYXX CITATION 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 AAEXX ABEEJ ADZGE |
ID | FETCH-LOGICAL-c375t-d08d183706a0a8939d832be607baf3c3b81fcf087ca40184352246627f894193 |
ISSN | 1078-8956 1546-170X |
IngestDate | Wed Aug 28 17:11:22 EDT 2024 Thu Oct 10 21:07:22 EDT 2024 Thu Sep 12 19:06:11 EDT 2024 Fri Oct 18 09:17:35 EDT 2024 Fri Oct 11 20:44:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c375t-d08d183706a0a8939d832be607baf3c3b81fcf087ca40184352246627f894193 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ORCID | 0000-0001-5931-386X 0000-0002-7005-0842 0000-0002-4295-0173 0000-0001-9908-597X 0000-0002-7514-1719 0000-0003-0532-5368 0000-0003-0139-5780 0000-0002-2263-6275 0000-0003-4116-1604 0000-0003-3691-8940 0000-0002-7266-395X 0000-0003-3335-369X 0000-0002-3911-748X 0000-0002-5923-3306 |
PMID | 38191615 |
PQID | 2917421867 |
PQPubID | 33975 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2912525321 proquest_journals_2917421867 crossref_primary_10_1038_s41591_023_02677_x pubmed_primary_38191615 springer_journals_10_1038_s41591_023_02677_x |
PublicationCentury | 2000 |
PublicationDate | 1-2024 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – year: 2024 text: 1-2024 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationTitle | Nature medicine |
PublicationTitleAbbrev | Nat Med |
PublicationTitleAlternate | Nat Med |
PublicationYear | 2024 |
Publisher | Nature Publishing Group US Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
References | Chang (CR16) 2019; 37 O’Meara, Tolaney (CR3) 2021; 12 Ramos-Casals (CR15) 2020; 6 Tang (CR8) 2020; 26 Schmid (CR5) 2018; 379 Sung (CR1) 2021; 71 Bian (CR14) 2019; 7 Liu (CR13) 2019; 11 Wang (CR17) 2023; 41 CR11 Cortes (CR7) 2022; 387 Sheng (CR10) 2020; 38 Waks, Winer (CR2) 2019; 321 Mai (CR12) 2021; 27 Miles (CR6) 2021; 32 Goodman (CR4) 2017; 16 Wang (CR9) 2021; 39 B Tang (2677_CR8) 2020; 26 2677_CR11 FH Wang (2677_CR9) 2021; 39 E Chang (2677_CR16) 2019; 37 AG Waks (2677_CR2) 2019; 321 L Bian (2677_CR14) 2019; 7 Z Wang (2677_CR17) 2023; 41 H Sung (2677_CR1) 2021; 71 X Sheng (2677_CR10) 2020; 38 D Miles (2677_CR6) 2021; 32 H-Q Mai (2677_CR12) 2021; 27 TA O’Meara (2677_CR3) 2021; 12 H Liu (2677_CR13) 2019; 11 M Ramos-Casals (2677_CR15) 2020; 6 J Cortes (2677_CR7) 2022; 387 AM Goodman (2677_CR4) 2017; 16 P Schmid (2677_CR5) 2018; 379 |
References_xml | – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: CR1 article-title: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 contributor: fullname: Sung – volume: 39 start-page: 704 year: 2021 end-page: 712 ident: CR9 article-title: Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.20.02712 contributor: fullname: Wang – volume: 6 start-page: 38 year: 2020 ident: CR15 article-title: Immune-related adverse events of checkpoint inhibitors publication-title: Nat. Rev. Dis. Prim. doi: 10.1038/s41572-020-0160-6 contributor: fullname: Ramos-Casals – volume: 387 start-page: 217 year: 2022 end-page: 226 ident: CR7 article-title: Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2202809 contributor: fullname: Cortes – volume: 11 start-page: 681 year: 2019 end-page: 690 ident: CR13 article-title: Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy publication-title: MAbs contributor: fullname: Liu – volume: 38 start-page: 5040 year: 2020 end-page: 5040 ident: CR10 article-title: Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: results of an open-label phase II clinical study Polaris-03 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.5040 contributor: fullname: Sheng – volume: 321 start-page: 288 year: 2019 end-page: 300 ident: CR2 article-title: Breast cancer treatment: a review publication-title: JAMA doi: 10.1001/jama.2018.19323 contributor: fullname: Winer – volume: 16 start-page: 2598 year: 2017 end-page: 2608 ident: CR4 article-title: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0386 contributor: fullname: Goodman – volume: 41 start-page: 651 year: 2023 end-page: 663 ident: CR17 article-title: Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.22.00727 contributor: fullname: Wang – volume: 12 start-page: 394 year: 2021 end-page: 400 ident: CR3 article-title: Tumor mutational burden as a predictor of immunotherapy response in breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.27877 contributor: fullname: Tolaney – ident: CR11 – volume: 27 start-page: 1536 year: 2021 end-page: 1543 ident: CR12 article-title: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial publication-title: Nat. Med. doi: 10.1038/s41591-021-01444-0 contributor: fullname: Mai – volume: 37 start-page: e20690 year: 2019 ident: CR16 article-title: FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e20690 contributor: fullname: Chang – volume: 7 start-page: 435 year: 2019 ident: CR14 article-title: JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial publication-title: Ann. Transl. Med. doi: 10.21037/atm.2019.09.08 contributor: fullname: Bian – volume: 26 start-page: 4250 year: 2020 end-page: 4259 ident: CR8 article-title: Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3922 contributor: fullname: Tang – volume: 379 start-page: 2108 year: 2018 end-page: 2121 ident: CR5 article-title: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa1809615 contributor: fullname: Schmid – volume: 32 start-page: 994 year: 2021 end-page: 1004 ident: CR6 article-title: Primary results from IMpassion131 a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2021.05.801 contributor: fullname: Miles – volume: 12 start-page: 394 year: 2021 ident: 2677_CR3 publication-title: Oncotarget doi: 10.18632/oncotarget.27877 contributor: fullname: TA O’Meara – volume: 7 start-page: 435 year: 2019 ident: 2677_CR14 publication-title: Ann. Transl. Med. doi: 10.21037/atm.2019.09.08 contributor: fullname: L Bian – volume: 26 start-page: 4250 year: 2020 ident: 2677_CR8 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3922 contributor: fullname: B Tang – ident: 2677_CR11 doi: 10.1002/cac2.12068 – volume: 321 start-page: 288 year: 2019 ident: 2677_CR2 publication-title: JAMA doi: 10.1001/jama.2018.19323 contributor: fullname: AG Waks – volume: 6 start-page: 38 year: 2020 ident: 2677_CR15 publication-title: Nat. Rev. Dis. Prim. doi: 10.1038/s41572-020-0160-6 contributor: fullname: M Ramos-Casals – volume: 41 start-page: 651 year: 2023 ident: 2677_CR17 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.22.00727 contributor: fullname: Z Wang – volume: 27 start-page: 1536 year: 2021 ident: 2677_CR12 publication-title: Nat. Med. doi: 10.1038/s41591-021-01444-0 contributor: fullname: H-Q Mai – volume: 38 start-page: 5040 year: 2020 ident: 2677_CR10 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.5040 contributor: fullname: X Sheng – volume: 16 start-page: 2598 year: 2017 ident: 2677_CR4 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0386 contributor: fullname: AM Goodman – volume: 379 start-page: 2108 year: 2018 ident: 2677_CR5 publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa1809615 contributor: fullname: P Schmid – volume: 32 start-page: 994 year: 2021 ident: 2677_CR6 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2021.05.801 contributor: fullname: D Miles – volume: 11 start-page: 681 year: 2019 ident: 2677_CR13 publication-title: MAbs contributor: fullname: H Liu – volume: 71 start-page: 209 year: 2021 ident: 2677_CR1 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 contributor: fullname: H Sung – volume: 37 start-page: e20690 year: 2019 ident: 2677_CR16 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e20690 contributor: fullname: E Chang – volume: 387 start-page: 217 year: 2022 ident: 2677_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2202809 contributor: fullname: J Cortes – volume: 39 start-page: 704 year: 2021 ident: 2677_CR9 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.20.02712 contributor: fullname: FH Wang |
SSID | ssj0003059 |
Score | 2.5460083 |
Snippet | The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 249 |
SubjectTerms | 692/308/2779/777 692/699/67/1347 Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Chemotherapy Confidence intervals Immune checkpoint inhibitors Infectious Diseases Metabolic Diseases Metastases Metastasis Molecular Medicine Neurosciences Paclitaxel PD-L1 protein Placebos Safety Statistical analysis Survival |
Title | Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial |
URI | https://link.springer.com/article/10.1038/s41591-023-02677-x https://www.ncbi.nlm.nih.gov/pubmed/38191615 https://www.proquest.com/docview/2917421867 https://www.proquest.com/docview/2912525321/abstract/ |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbysZeytbd0nVDg71l3nyRfNlbOxpKaTMKLoS9GEmWN8Nqh9SGpL9-R5fY6dxBtxcT5GAZf590bjrnIPSB-EXsSrBUaSISh1CZw5rjvsNZQUlO86TQTfvOZ-HJJTmd03nv0NfZJQ3_JG7uzCv5H1RhDHBVWbL_gGz3UBiA34AvXAFhuN4P4xqWPCjSV4xPFr9UqVXGHTCCVeHtlVTVNFSHaKaShkqhTp4vlXdd12NqlsrD7lTyh6n8zdXh9EadARNyaTKgQYrl9VV5Ayrp4icIu0kw0T0-tvXZma4LOojQn5bWDf1dFrLsHLnt2g5ftDrhuI9ImR7JrB74sS9AtK5bS2HrnfDJlnfCbqgkdLzInRt5c8eY3YVtdGabbXZLNSVNB1u9Kex-DQqIOrvlq2h0GEXOqhdsm2D-7Fs2vTw7y9LjefoQ7fhRQukI7RxOj45mndSGfS_RtXXtu9kEK5jl83CO20rMwDIZRNW1spI-RbvWysCHhjLP0ANZ7aFHpu_oeg89Prd4PUfNFoew4hC-zSFcVrjnEK6XuOMQ_oND2HAIGw59wQz3DMKaQTjAmkEvUDo9Tr-eOLYThyOCiDZO7sa5p8okhcxloOEmOQgCLkM3gjUdiIDHXiEKN44EA3s9JkqrJ6q1QBEnBEyEl2hU1ZV8jXDuhTGRASORAF0WLDtGPCI4pyJIwqRwx2iy-bLZwtRbyfQ5iSDODA4Z4JBpHLLVGB1sPn5m1-V15idgZatWa9EYve9uw66pQmGsknWr_-NTnwa-N0avDGjddNqHAYr-GH3coNg__O_vsn-Pyd6gJ_0iOUCjZtnKt6DUNvyd5eNvIcGg-w |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toripalimab+plus+nab-paclitaxel+in+metastatic+or+recurrent+triple-negative+breast+cancer%3A+a+randomized+phase+3+trial&rft.jtitle=Nature+medicine&rft.au=Jiang%2C+Zefei&rft.au=Ouyang%2C+Quchang&rft.au=Sun%2C+Tao&rft.au=Zhang%2C+Qingyuan&rft.date=2024-01-01&rft.issn=1546-170X&rft.eissn=1546-170X&rft.volume=30&rft.issue=1&rft.spage=249&rft_id=info:doi/10.1038%2Fs41591-023-02677-x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-8956&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-8956&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-8956&client=summon |